ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including  Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PSX). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs.

For more information, please refer to the English press release.